Key Points
- Terilyn Monroe sold 10,031 shares of Guardant Health on Jan. 7 at an average price of $112.08 for about $1.124M, leaving her with 20,990 shares—a 32.34% reduction in her ownership per an SEC filing.
- Guardant Health recently traded near $110 (one‑year range $34.80–$113.91) with a $13.89B market cap, and it reported quarterly EPS of ($0.39) that beat estimates while revenue grew 38.5% year‑over‑year.
- Analyst sentiment is predominantly positive—22 Buys, 1 Hold and 1 Sell with an average price target of $102.81 (some firms raised targets up to $155)—and institutional investors hold about 92.6% of the shares.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) insider Terilyn Monroe sold 10,031 shares of the stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $112.08, for a total transaction of $1,124,274.48. Following the sale, the insider directly owned 20,990 shares in the company, valued at $2,352,559.20. This trade represents a 32.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Guardant Health Stock Performance
NASDAQ GH opened at $110.17 on Friday. Guardant Health, Inc. has a one year low of $34.80 and a one year high of $113.91. The company has a 50-day simple moving average of $102.14 and a 200-day simple moving average of $73.15. The firm has a market capitalization of $13.89 billion, a PE ratio of -34.32 and a beta of 1.58.
Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.09. During the same quarter in the prior year, the firm posted ($0.88) earnings per share. Guardant Health's revenue for the quarter was up 38.5% compared to the same quarter last year. Equities analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.
Analysts Set New Price Targets
A number of research analysts recently issued reports on GH shares. Evercore ISI set a $105.00 price objective on Guardant Health and gave the company an "in-line" rating in a research report on Monday. Weiss Ratings reissued a "sell (d-)" rating on shares of Guardant Health in a report on Wednesday, October 8th. Leerink Partners upped their price target on shares of Guardant Health from $115.00 to $155.00 and gave the stock an "outperform" rating in a research report on Monday, December 15th. Morgan Stanley increased their price objective on shares of Guardant Health from $105.00 to $130.00 and gave the stock an "overweight" rating in a report on Monday, December 1st. Finally, Guggenheim boosted their target price on shares of Guardant Health from $85.00 to $115.00 and gave the company a "buy" rating in a research note on Monday. Twenty-two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $102.81.
Get Our Latest Analysis on GH
Institutional Investors Weigh In On Guardant Health
A number of hedge funds and other institutional investors have recently modified their holdings of GH. Intech Investment Management LLC raised its holdings in Guardant Health by 37.3% during the first quarter. Intech Investment Management LLC now owns 60,187 shares of the company's stock worth $2,564,000 after purchasing an additional 16,363 shares in the last quarter. Edgestream Partners L.P. boosted its stake in Guardant Health by 147.3% during the 2nd quarter. Edgestream Partners L.P. now owns 50,519 shares of the company's stock valued at $2,629,000 after purchasing an additional 30,094 shares in the last quarter. State of Wyoming acquired a new position in shares of Guardant Health during the 2nd quarter valued at $567,000. Yorktown Management & Research Co Inc bought a new stake in shares of Guardant Health in the 2nd quarter worth $289,000. Finally, Osterweis Capital Management Inc. acquired a new stake in shares of Guardant Health in the first quarter valued at $12,634,000. 92.60% of the stock is currently owned by institutional investors.
Guardant Health Company Profile
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
